Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?
Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases.…
31,725€
0,05%
Echtzeit-Aktienkurs Crinetics Pharmaceuticals Inc.
Bid:
Ask:
Nachrichten zur Crinetics Pharmaceuticals Inc. Aktie
Crinetics (CRNX) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool.DATEThursday, Feb. 26, 2026 at 4:30 p.m. ETCall participantsChief Executive Officer — R. Scott StruthersChief Financial…
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Beats Revenue Estimates
CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of +6.01% and +38.05%, respectively, for the quarter ended December 2025. Do…
Crinetics Pharma - Zulassungserfolg für Palsonify sollte Ergebnis anschieben!
Geschäftstreiber: Crinetics Pharmaceuticals (CRNX) hat sich auf die Entdeckung, Entwicklung und Vermarktung neuer Therapeutika für endokrine Erkrankungen und endokrin bedingte Tumore fokussiert....…
Crinetics Pharmaceuticals prices public offering at $45.95 per share By Investing.com
Crinetics Pharmaceuticals prices public offering at $45.95 per share…
Crinetics Pharmaceuticals, Inc. (CRNX) Discusses PALSONIFY Launch Progress and Phase 2 Atumelnant Results in Congenital Adrenal Hyperplasia Transcript
…
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that the company…
Crinetics Pharmaceuticals stock falls after CMO departure announcement By Investing.com
Crinetics Pharmaceuticals stock falls after CMO departure announcement…
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Dec. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on…
Crinetics Pharmaceuticals: Potenzial nach FDA-Zulassung?
Crinetics Pharmaceuticals hat in den vergangenen Monaten bedeutende Fortschritte erzielt. Allen voran die erfolgreiche US-Zulassung von Paltusotin zur Behandlung von…
Is Crinetics Pharmaceuticals Stock a Buy?
The FDA just handed this clinical-stage biotech its golden ticket -- but at a $4.3 billion valuation, the markets already…
Is Crinetics Pharmaceuticals Stock a Buy? @themotleyfool #stocks $CRNX
The FDA just handed this clinical-stage biotech its golden ticket -- but at a $4.3 billion valuation, the markets already…
Crinetics Pharmaceuticals: Citizens JMP sieht in der FDA-Zulassung von Palsonify einen adressierbaren Markt von über 3 Mrd. USD!
Crinetics Pharmaceuticals Inc. (CRNX) kann momentan dank der Zulassung ihres Hauptmedikaments Palsonify (Paltusotine) durch die US-amerikanische Food and Drug Administration…
Crinetics Pharmaceuticals, Inc. (CRNX) Discusses On PALSONIFY FDA Approval Call Transcript
…
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates
CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of -8.85% and -79.78%, respectively, for the quarter ended June 2025. Do…
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June…
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April…
Crinetics Pharmaceuticals, Inc (CRNX) Q4 2024 Earnings Call Transcript
…
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January…
Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness
…
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December…
Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2024 Earnings Call Transcript
…
Crinetics Pharmaceuticals Inc.: Erwarteter Umsatzanstieg von 4 Mio. auf 160 Mio. USD dank bevorstehender Markteinführung
Mit seinen innovativen Therapien für unterversorgte Zielgruppen hat der Megatrend Biopharmazeutika bereits einige attraktive Anlageoptionen für Investoren hervorgebracht. Allen voran…
Crinetics Pharmaceuticals prices $500M equity at $50 per share
…
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused…
Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on September…
Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2024 Earnings Call Transcript
…
Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July…
Crinetics Pharmaceuticals exec sells shares worth over $645,000 By Investing.com
Crinetics Pharmaceuticals exec sells shares worth over $645,000…
Crinetics Pharmaceuticals files for mixed shelf, to sell shares for holders
…
Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June…
Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2024 Earnings Call Transcript
…
Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May…
How to Invest in Biotechnology (Updated 2024)
Investors interested in the life science sector are well aware of the importance of biotechnology.From finding cures for diseases to…
Crinetics Pharmaceuticals exec sells over $664k in company stock By Investing.com
Crinetics Pharmaceuticals exec sells over $664k in company stock…
Crinetics Pharmaceuticals director Fust sells shares worth over $2.6m By Investing.com
Crinetics Pharmaceuticals director Fust sells shares worth over $2.6m…
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMYs CAR T Cell Therapy News & More
Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.…
Crinetics Pharmaceuticals CFO sells shares worth nearly $300k By Investing.com
Crinetics Pharmaceuticals CFO sells shares worth nearly $300k…
Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?
Crinetics Pharmaceuticals (CRNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings…
Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2023 Earnings Call Transcript
…
Crinetics Pharmaceuticals secures $350 million in placement By Investing.com
Crinetics Pharmaceuticals secures $350 million in placement…